Who are Glucophage tablets and Victoza's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/glucophage-tablets-and-victoza.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Glucophage tablets and Victoza — Competitive Intelligence Brief

Glucophage tablets and Victoza (Glucophage tablets and Victoza) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Biguanide (metformin) and GLP-1 receptor agonist (liraglutide). Area: Diabetes.

marketed Biguanide (metformin) and GLP-1 receptor agonist (liraglutide) AMP-activated protein kinase (metformin); GLP-1 receptor (liraglutide) Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Glucophage tablets and Victoza (Glucophage tablets and Victoza) — University Medical Centre Ljubljana. Glucophage (metformin) reduces hepatic glucose production and improves insulin sensitivity, while Victoza (liraglutide) stimulates insulin secretion and reduces glucagon in response to blood glucose levels.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Glucophage tablets and Victoza TARGET	Glucophage tablets and Victoza	University Medical Centre Ljubljana	marketed	Biguanide (metformin) and GLP-1 receptor agonist (liraglutide)	AMP-activated protein kinase (metformin); GLP-1 receptor (liraglutide)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Biguanide (metformin) and GLP-1 receptor agonist (liraglutide) class)

University Medical Centre Ljubljana · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Glucophage tablets and Victoza — Competitive Intelligence Brief. https://druglandscape.com/ci/glucophage-tablets-and-victoza. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab